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Abstract 
Background:Cholesterol has essential functions in neurological processes that require tight regulation of 
synthesis and metabolism. Perturbed cholesterol homeostasis has been demonstrated in Huntington's 
disease, however the exact role of these changes in disease pathogenesis is not fully understood. 
Objective:This study aimed to comprehensively examine changes in cholesterol biosynthetic precursors, 
metabolites and oxidation products in the striatum and cortex of the R6/1 transgenic mouse model of 
Huntington's disease. We also aimed to characterise the progression of the physical phenotype in these 
mice. Methods:GC-MS/MS was used to quantify a broad range of sterols in the striatum and cortex of R6/
1 and wild type mice at 6, 12, 20, 24 and 28 weeks of age. Motor dysfunction was assessed over 28 
weeks using the RotaRod and the hind-paw clasping tests. Results:24(S)-Hydroxycholesterol and 
27-hydroxycholesterol were the major cholesterol metabolites that significantly changed in R6/1 mice. 
These changes were specifically localised to the striatum and were detected at the end stages of the 
disease. Cholesterol synthetic precursors (lathosterol and lanosterol) were significantly reduced in the 
cortex and striatum by 6 weeks of age, prior to the onset of motor dysfunction, as well as the cognitive 
and affective abnormalities previously reported. Elevated levels of desmosterol, a substrate of delta(24)-
sterol reductase (DHCR24), were also detected in R6/1 mice at the end time-point. Female R6/1 mice 
exhibited a milder weight loss and hind paw clasping phenotype compared to male R6/1 mice, however, 
no difference in the brain sterol profile was detected between sexes. Conclusion:Several steps in 
cholesterol biosynthetic and metabolic pathways are differentially altered in the R6/1 mouse brain as the 
disease progresses and this is most severe in the striatum. This provides further insights into early 
molecular mediators of HD onset and disease progression and identifies candidate molecular targets for 
novel therapeutic approaches. 
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Background: Cholesterol has essential functions in neurological processes that require tight 
regulation of synthesis and metabolism. Perturbed cholesterol homeostasis has been 
demonstrated in Huntington’s disease, however the exact role of these changes in disease 
pathogenesis is not fully understood.  
Objective: This study aimed to comprehensively examine changes in cholesterol biosynthetic 
precursors, metabolites and oxidation products in the striatum and cortex of the R6/1 
transgenic mouse model of Huntington’s disease. We also aimed to characterise the 
progression of the physical phenotype in these mice. 
Methods: GC-MS/MS was used to quantify a broad range of sterols in the striatum and cortex 
of R6/1 and wild type mice at 6, 12, 20, 24 and 28 weeks of age. Motor dysfunction was 
assessed over 28 weeks using the RotaRod and the hind-paw clasping tests.  
Results: 24-Hydroxycholesterol and 27-hydroxycholesterol were the major cholesterol 
metabolites that significantly changed in R6/1 mice. These changes were specifically 
localised to the striatum and were detected at the end stages of the disease. Cholesterol 
synthetic precursors (lathosterol and lanosterol) were significantly reduced in the cortex and 
striatum by 6 weeks of age, prior to the onset of motor dysfunction, as well as the cognitive 
and affective abnormalities previously reported. Elevated levels of desmosterol, a substrate of 
delta(24)-sterol reductase (DHCR24), were also detected in R6/1 mice at the end time point. 
Female R6/1 mice exhibited a milder weight loss and hind paw clasping phenotype compared 
to male R6/1 mice, however, no difference in the brain sterol profile was detected between 
sexes.  
Conclusion: Several steps in cholesterol biosynthetic and metabolic pathways are 





in the striatum. This provides further insights into early molecular mediators of HD onset and 




Huntington’s disease (HD) is a progressive neurodegenerative disease caused by the 
expansion of a trinucleotide [cytosine-adenine-guanidine (CAG)] repeat on the N-terminus of 
the huntingtin protein (HTT). The classical neuropathological hallmark of HD is the severe 
atrophy of the striatum (caudate and putamen) [1], with substantial volume loss in the order 
of 50%. This primarily manifests as involuntary movements (chorea) and cognitive 
dysfunction. MRI techniques have also highlighted that the hippocampus, cerebral cortex, 
globus pallidus and amygdala also have reduced volume in HD patients [2]. Among other 
effects, the expansion of the CAG repeat on HTT has been reported to alter HTT-
phospholipid interactions [3], membrane organisation [4] and gene transcription of lipid 
metabolic enzymes [5]. Several studies have also identified that cholesterol synthesis and 
metabolism in HD cell lines and animal models is significantly disturbed [6-8] highlighting 
possible mechanisms. However, further investigation into different sterol-related mechanisms 
and metabolic pathways is necessary to examine their influence on HD pathophysiology. 
Cholesterol is highly concentrated in the brain, the majority found in myelin, accounting for 
70% of total cholesterol, with the remainder found in cellular membranes of neurons and glial 
cells. Maintenance of cholesterol levels is essential for many neurological functions including 
dendritic maintenance [9], synaptogenesis [10] and axon growth [11]. Genetic defects that 
alter cholesterol synthetic enzymes can have severe consequences [12,13], especially in the 





The blood brain barrier (BBB) is impermeable to cholesterol, preventing fluctuations in 
circulating cholesterol affecting brain levels. Brain cholesterol is derived from de novo 
synthesis, a pathway that involves over 20 steps. Cholesterol biosynthetic regulation is 
thought to involve a complex interplay between sterol sensing elements [sterol regulatory 
element-binding proteins (SREBPs)] and transcription factors responsible for producing 
cholesterol synthetic enzymes [14]. However, recent evidence suggests that further regulation 
of cholesterol synthesis may occur in the later stages of the pathway [15,16]. The later stages 
of the cholesterol biosynthetic pathway are branched into the Kandutsch-Russell and Bloch 
pathways. Several cholesterol synthetic precursors exist in these pathways that occur 
downstream of squalene (see Fig. 1). Although the rate of cholesterol synthesis in peripheral 
tissues can be estimated by plasma levels of cholesterol synthetic precursors (lathosterol and 
lanosterol), these do not reflect central nervous system (CNS) cholesterol synthesis. Direct 
measurement of sterol precursor levels in brain tissue is therefore necessary to monitor the 
cholesterol synthetic pathway [7,8,17].  
24-Hydroxycholesterol (24-OHC) has been marked as a molecule of interest after being 
identified as a major and specific elimination product of cholesterol from the brain [18,19]. 
Side chain hydroxylation of cholesterol increases membrane permeability and enables 
movement across the BBB into circulation.  24-OHC is formed enzymatically from CNS 
cholesterol catalysed by cholesterol 24-hydroxylase (CYP46A1), which is primarily 
expressed in neurons [20]. Plasma 24-OHC levels have been suggested as a marker of 
metabolically active neurons in the brain [19], and have been shown to be reduced in the 
plasma of HD patients [21,22] and in brain tissue of several rodent models of HD [8]. 
Furthermore, an association between altered CYP46A1 activity and 24-OHC levels has been 
reported in other neurodegenerative diseases [23-26], however the role of these changes in 





27-Hydroxycholesterol (27-OHC) is a major metabolic product of cholesterol in peripheral 
tissue, entering the bloodstream to be further metabolised in the liver [27,28]. The enzyme 
cholesterol 27-hydroxylase (CYP27A1) catalyses the formation of 27-OHC. A concentration 
gradient results in a net movement of 27-OHC from circulation into the brain [29], where it is 
quickly metabolised into more polar products (including dihydroxysterols and cholestenoic 
acids), catalysed by CYP27A1 and 5-hydroxycholesterol 7-α-hydroxylase (CYP7B1) [30]. 
Although 27-OHC has been reported to be elevated in Alzheimer’s disease (AD) brain tissue 
[31,32], the importance of this metabolic pathway has not been established in other 
neurodegenerative diseases, including HD.  
Oxidative damage to biological macro molecules is a major component of neurodegenerative 
diseases, including AD [33] and Parkinson’s disease (PD) [34]. Free radical mediated 
oxidation of cholesterol in the 5,6 position forms 7β-hydroxycholesterol (7β-OHC) and 7-
ketocholesterol (7-KC). An elevation of these cholesterol oxidation products (COPs) has been 
reported in several diseases and pathological models that involve oxidative stress [35-38]. 
Due to the high concentration of cholesterol in the brain, COPs represent potentially 
important biomarkers for oxidative stress in neurodegenerative diseases. 
Perturbed cholesterol synthetic and metabolic pathways have been previously reported in HD 
mouse and cell models [5-7,17]. Due to the complexity of the cholesterol synthetic pathway, 
previous studies have measured some of the major brain synthetic sterol intermediates and 
metabolites, but the full extent of potential sterol alterations that may occur in different brain 
regions has not been fully examined. In this study we have used an accurate and sensitive 
GC-MS/MS technique to characterise cholesterol pathway alterations occurring in the 
striatum and cortex of the R6/1 mouse model. Physical phenotypic changes were also 
examined including, impaired motor performance, weight loss, reduced brain mass and 





to establish when specific alterations of cholesterol synthetic and metabolic pathways may 
occur during the progression of HD in the R6/1 mouse model.  
 
Materials and Methods 
Materials 
Desmosterol-d6, zymosterol-d5, zymosterol and lanosterol-d6 were obtained from Avanti 
lipids (Alabaster, AL, USA). Tert-butylhydroxytoluene (BHT), cholesterol, -cholestane, 7-
hydroxycholesterol, 7-dehydrocholesterol and 7-ketocholesterol were from Sigma (St. Louis, 
MO, USA). Lathosterol, lanosterol, desmosterol and 27-hydroxycholesterol were obtained 
from Steraloids (Newport, RI, USA). 7-hydroxycholesterol-d7, lathosterol-d4 and 7-
ketocholesterol-d7 were purchased from CDN Isotopes (Quebec, Canada). 27-
hydroxycholesterol-d5, 24-hydroxycholesterol and 24-hydroxycholestero-d7 were from 
Medical Isotopes, Inc (Pelham, AL, USA). 24,25-dihydrolanosterol-d6 was obtained from 
Toronto research chemicals (TRC, Ontario, Canada). All standards obtained were of the 
highest purity (>95%). Methanol, hexane, methyl tert-butyl ether (MTBE), acetonitrile, 
toluene, formic acid and NaOH were purchased from Ajax Finechem (Thermo Fisher 
Scientific, AU). CUQAX223 UCT Clean-Up QAX2 solid phase extraction columns and 
BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide) + 1% TMCS  (trimethylchlorosilane) 
was purchased from PM Separations (Qld, Australia). 
Mice 
Transgenic R6/1 male mice were provided by the Hannan Laboratory, Florey Institute of 
Neurosciences and Mental Health, and bred with CBB6 (CBA x C57/B6) F1 female mice at 





wild type mice were housed in standard small rodent cages. At least two of each genotype 
was housed per cage. Mice were provided with standard rodent diet ("rat & mouse nut", Vella 
Stock Feeds, NSW, Australia) and water available ad libitum. Body weight was recorded 
every 4-5 days from 7 weeks until sacrifice. All procedures that were undertaken conformed 
to the standards of the University of Wollongong ethics committee (animal ethics approval 
number: AE 13/20). 
Behavioural testing 
A RotaRod apparatus (TSE systems, Bad Homberg, Germany) was used to measure motor 
performance of mice. Mice were acclimatised to the RotaRod over two days before initial 
testing. The testing protocol involved a rotation of 4 RPM for 5 sec followed by a linear 
acceleration from 4 to 40 RPM over 200 sec. The latency to fall was measured automatically 
by the RotaRod using light beam sensors. This procedure was repeated (5 times in total) and 
the average of the two longest run times was recorded for analysis. The hind paw clasping 
phenotype was tested by suspending the mouse by the tail. Mice that clasped both hind paws 
tightly to their body were considered to have a complete clasp phenotype. Mice that clasped 
one paw or both paws in an interrupted manner were considered to have a "half clasp" 
phenotype. 
Brain tissue collection 
Mice were euthanised using slow flow CO2 asphyxiation and perfused with 1 x PBS (4
oC). 
The head was then excised and the whole brain removed and weighted. Cerebral cortex and 
striatum was dissected and snap frozen in liquid N2 and stored at -80
oC prior to analysis. 
Lipid extraction 
Frozen brain tissue (~5-10 mg) was weighed directly into a 0.5 mL polypropylene tube 





methanol (0.01% BHT) and internal standards (4oC). Tissue was homogenised at 4°C using a 
Precellys 24 homogeniser (Bertin Technologies) (2 x 20 s at 5,000 rpm) and the homogenate 
was transferred to a clean glass vial. The tube and ceramic beads were washed with 100 µL 
methanol (4°C) and was added to the homogenate with 250 µL of NaOH (1 M). The sample 
was hydrolysed at room temperature for 16 h in the absence of light and then acidified with 
330 µL of 1 M formic acid. The sample was made up to a final volume of 3 mL (8% 
methanol, pH 4.5) by the addition of 2.2 mL milliQ water. Solid-phase extraction (SPE) was 
carried out on a 200 mg mixed C8/anion exchange quaternary amine column (CUQAX223, 
UCT Inc.) that had been preconditioned with 2 mL methanol and then 2 mL 40 mM formic 
acid buffer (pH 4.5). The lipid extract was loaded and the column washed with 2 mL 
methanol in 40 mM formic acid (40:60). The SPE column was dried with N2 gas flow for 5 
min. Sterols and oxysterols were eluted in a single fraction with 2 mL hexane followed by 2 
mL hexane/MTBE (50:50). 
GC-MS/MS sterol analysis 
The sterol/oxysterol fraction was dried under N2 gas flow at 37°C and derivatised by the 
addition of 20 µL acetonitrile and 20 µL BSTFA + 1% TMCS  for one hour at 37oC. Samples 
were dried under N2 and immediately reconstituted in 40 µL toluene for GC-MS/MS 
analysis. Selective reaction monitoring (SRM) analysis of sterols/oxysterols was carried out 
on an Agilent 7000B triple quadrupole mass selective detector interfaced with an Agilent 
7890A GC system gas chromatograph. Quantification was performed by Agilent Masshunter 
Quantitative software (V B.05.00) by comparison of specific SRM transitions with their 
corresponding heavy isotopes and using relative response factor calibration. Cholesterol was 
quantified using the internal standard α-cholestane in a separate injection and 






Linear regression analysis was used to identify the rate of weight gain between genotypes and 
identify the relationship between age and sterol changes in mice. A 2-way ANOVA was used 
to analyse RotaRod performance, body weight, brain lipid and brain mass data, with 
Bonferroni post-tests to compare means at individual time points. A student’s t test was also 
used to compare sterols levels between sexes and at individual time points in the sterol data. 
P-values < 0.05 were considered significant. All analyses were performed in Graphpad 




The cohort of R6/1 and WT littermates housed until 28 weeks of age (n = 5 per genotype and 
sex) were tested periodically for physical changes that characterise the progression of the HD 
phenotype. These results are represented in Fig. 2.   
Weight loss in R6/1 mouse 
Male and female R6/1 body weight was significantly reduced compared to WT mice over the 
course of the study (p < 0.0001, Fig. 2A). The mean body weight of R6/1 mice did not 
increase after 16 weeks of age in males, and 19 weeks in females. Prior to weight loss (7-19 
weeks) the rate of weight gain was significantly less in female R6/1 mice compared to WT (p 
= 0.00012). No significant difference in the rate of weight gain was detected between male 
R6/1 and WT mice in the 6-16 week period. By 28 weeks the average weight increase from 
the earliest measurement (7 weeks) was 8% in R6/1 males and 19% in R6/1 females. 





The hind-paw clasping phenotype was previously observed in R6/1 and R6/2 mice [39]. In 
our study the clasping phenotype was first observed at 12 weeks in males (Fig. 2B), with the 
percentage of mice showing positive for the phenotype increasing to 60% at the end of the 
study. Female R6/1 mice first exhibited the clasping phenotype at the age of 17 weeks (Fig. 
2B). The percentage of female R6/1 mice showing the phenotype increased to 60% by the 
end of the study. A small proportion of WT mice showed a positive "half clasp" phenotype at 
varying times throughout the study. 
Motor performance 
The average latency to fall from the RotaRod was significantly less in R6/1 mice compared to 
WT in both males (p = 0.0016) and females (p = 0.0004) over the course of the study (Fig. 
2C). No difference in the RotaRod performance was detected between genders of the same 
genotype. 
Brain mass 
The brain mass of both male and female R6/1 mice was significantly less than WT littermates 
at later time points (Fig. 3). The difference between WT and R6/1 male mice was highly 
significant at 20, 24 and 28 weeks (p < 0.0001). In female mice a significant difference was 
detected at 12 and 20 weeks (p < 0.05), becoming highly significant at 24 and 28 weeks (p < 
0.0001).  
 
Sterol analysis of R6/1 brain tissue 
Tissues from both male and female R6/1 and WT mice were investigated in the sterol 
analysis. Minor differences in the sterol profile between male and female mice of the same 





differences identified between WT and R6/1 mice. Therefore to increase statistical power, 
both sexes were combined and reanalysed. The level of all sterols measured for the individual 
sexes can be found in Supplemental Table 1-2. The following results summarise the data for 
combined sexes.  
 
Cholesterol synthetic precursors 
Several cholesterol synthetic precursors were significantly decreased in R6/1 striatum and 
cortex compared to WT (Figs. 3.5A-D, 3.6A-D). Lathosterol levels were significantly 
reduced from the pre-symptomatic age of 6 weeks in R6/1 striatum (p < 0.001) and cortex (p 
< 0.05) when compared to WT mice. Lathosterol was consistently reduced in both cortex and 
striatum of R6/1 mice compared to WT at all later time points (12, 20, 24 and 28 weeks; p < 
0.001, Figs. 4A, 5A). Lanosterol and zymosterol followed a similar consistent reduction; a 
significant difference in lanosterol levels was first detected at 12 weeks in striatum (Fig. 4B) 
and cortex (Fig. 5B) of R6/1 (striatum p < 0.01, cortex p < 0.05). R6/1 striatum exhibited an 
early reduction in zymosterol at 6 weeks (p < 0.01), and at all later time points (Fig. 4C). The 
level of zymosterol in cortex tissue was only significantly reduced compared to WT at 28 
weeks of age (p < 0.05, Fig. 5C). The cholesterol synthetic precursor 24,25 dihydro lanosterol 
was not significantly altered in the R6/1 striatum or cortex although it was detected at lower 
mean levels than WT at all time-points examined (Figs. 4D, 5D). 
Lathosterol, lanosterol, zymosterol and 24,25 dihydro lanosterol levels decreased over time in 
the striatum of both WT and R6/1 mice (Fig. 4A-D, p < 0.01). In the cortex, lanosterol, 
zymosterol and 24, 25 dihydro lanosterol decreased significantly over time in R6/1 mice but 
not WT (Fig. 5B, C, D, p < 0.05). Lathosterol decreased significantly over time in the cortex 





Unlike upstream sterols in the cholesterol synthetic pathway, desmosterol levels did not 
significantly decrease over time in the striatum of R6/1 mice (Fig. 4E). Comparing the means 
between R6/1 and WT mice at individual time points identified desmosterol was significantly 
elevated in R6/1 striatum at 20 and 28 weeks compared to WT (t-test, p = 0.046 and p = 
0.0138 respectively, Fig. 4E). Desmosterol levels in cortex were also unaltered over time in 
both WT and R6/1 mice. A small but significant elevation of desmosterol was detected in 
R6/1 mice at 28 weeks (t-test, p = 0.0431, Fig. 5E).  7-dehydrocholesterol levels did not 
decrease over time in cortex or striatum of R6/1 mice, and no difference between R6/1 and 
WT mice was detected at any time point (Figs. 4F, 5F). 
Cholesterol 
Total cholesterol levels were not significantly altered between R6/1 and WT mice in this 
study. However, an increase in cholesterol levels over time (6-28 weeks of age) was observed 
both in striatum and cortex of WT and R6/1 mice (p < 0.05, Fig. 6).  
Cholesterol metabolites 
The brain specific cholesterol elimination product 24-OHC was significantly reduced in the 
striatum of R6/1 mice at the end time point of 28 weeks (p < 0.01, Fig. 6). No other time 
point or brain region measured showed an effect of genotype on 24-OHC levels. 24-OHC 
levels increased in both striatum and cortex of WT and R6/1 mice over time (p < 0.01, Fig. 
6). 
27-OHC, a predominantly peripheral metabolite of cholesterol was consistently reduced in 
R6/1 striatum from the age of 12 weeks (p < 0.05) and at all later time points (20 weeks p < 
0.01, 24 weeks p < 0.05, 28 weeks p < 0.05, Fig. 6). 27-OHC levels were not significantly 
altered in cortex tissue of R6/1 mice when compared to WT at any of the 5 time-points 





Cholesterol oxidation products 
Free radical generated oxidation products of cholesterol were also measured over the course 
of the study. No significant differences in the level of 7-KC and 7β-OHC were detected 
between R6/1 and WT in any brain region or timepoint measured (Supplemental Table 1-3).  
 
Discussion 
This is the first study to comprehensively examine progressive sterol changes in the R6/1 
mouse model, and has investigated a greater number of cholesterol synthetic precursors and 
metabolites than other studies of HD animal models to date. Previous studies examining 
cholesterol changes in HD mouse models have focused on several major sterols in whole 
brain homogenates at multiple time-points during disease progression, or in specific brain 
regions at a single time-point. Recent studies suggesting more complex cholesterol synthetic 
regulation in the later stages of the cholesterol synthetic pathway [15,16] highlights the 
relevance of this study investigating a wider variety of cholesterol synthetic precursors.  
Minor sterol differences between sexes did not influence differences detected between R6/1 
and WT mice. Therefore, for simplicity the following discussion describes changes occurring 
when sexes were combined. The significant reduction of lathosterol and zymosterol in the 
striatum of R6/1 mice at 6 weeks of age represents the earliest detectable change in the R6/1 
sterol profile, and appears before the onset of overt motor dysfunction as measured on the 
RotaRod. In fact, 6 weeks of age in R6/1 mice also precedes the onset of cognitive deficits 
[40,41] and affective abnormalities [42,43] in this HD model and therefore this sterol 
dysregulation could contribute to cognitive, psychiatric and motor symptoms. Changes to 





in both cortex and striatum. This highlights zymosterol as a possible specific biomarker of 
early striatal changes in HD mice. 
Synthetic precursor levels were more severely affected in striatum compared to cortex in our 
study; changes occurred earlier and were of a greater magnitude in striatum (lathosterol 
decreased by 80% in striatum compared with 50% in cortex). This observation is consistent 
with previous studies in the yeast artificial chromosome (YAC 128) and R6/2 transgenic HD 
mouse models [7,17]. The striatum is also the earliest and most severely affected region in 
HD [1]. Absolute cholesterol and cholesterol synthetic precursor levels have been shown to 
be higher in striatum compared to cortex [7,44], and for this reason it has been hypothesised 
that disturbed cholesterol homeostasis in HD may lead to specific vulnerability of the 
striatum [7]. Significant sterol changes early in the striatum of the R6/1 mouse suggest that 
alterations to the cholesterol biosynthetic pathway in the brain occur very early; with the 
possibility that these changes may even be present during embryonic development. Since the 
majority of brain cholesterol is synthesised during prenatal life [45], HD neurodegeneration 
may be seeded early, with individuals only becoming symptomatic later in life. A current 
hypothesis suggests that errors in myelination during development may be a factor in human 
HD, taking many years to manifest before onset due to compensatory mechanisms that 
function early but become overwhelmed in the aged brain [46]. Alternatively, early changes 
to cholesterol biosynthesis may be independent of the pathological processes in this HD 
model.  
This study has also examined 7-dehydrocholesterol and desmosterol; the immediate 
precursors to cholesterol in the Kandutsch-Russell and Bloch pathways respectively (Fig. 1). 
Contrary to a previous finding that desmosterol decreases in symptomatic YAC 128 mice (10 
months of age) [17], desmosterol levels were significantly elevated in R6/1 striatum and 





expressing different forms of mutant HTT (truncated or full length). In addition, analytical 
discrimination of very similar sterols such as 7-dehydrocholesterol and desmosterol can be 
challenging. The use of GC-MS/MS in our study provides greater specificity than single 
quadrupole GC-MS that was used in the previous study [17]. Desmosterol elevation in R6/1 
mice is unlikely a result of increased synthesis as cholesterol levels did not increase in our 
study or in a previous study examining R6/1 mice [4]. A plausible explanation for this 
accumulation is a reduced activity of the enzyme (DHCR24) that catalyses the conversion of 
desmosterol to cholesterol.  Previous studies in R6/2 mice do not report desmosterol levels 
and therefore it is unknown if desmosterol accumulation also occurs in this related HD mouse 
model that expresses a longer CAG repeat in the R6 transgene [7]. 7-Dehydrocholesterol 
levels have not been previously reported in HD mouse brain, and in contrast to upstream 
Kandutsch-Russell branch precursors the levels were not significantly altered over time and 
between WT and R6/1 mice. Since lathosterol (the immediate precursor of 7-
dehydrocholesterol) levels are substantially reduced the enzyme that converts 7-
dehydrocholesterol to cholesterol (DHCR7) may also be less active or at lower abundance in 
R6/1 mice.  
The absolute level of cholesterol synthetic precursors (lathosterol and lanosterol) in brain 
tissue has been proposed as a marker of the cholesterol synthetic rate [7,47]. However our 
results suggest there is likely to be more complex regulation at various points of the synthetic 
pathway (Fig. 1) than previously considered. Measurement of individual precursors alone to 
interpret synthetic rate may be potentially confounding. The cellular regulation of cholesterol 
synthesis occurring downstream of squalene has been investigated recently and identified the 
two terminal enzymes in the pathway interact functionally, DHCR24 regulating the activity 
of 7-dehydrocholesterol reductase (DHCR7) [16]. DHCR24 is also believed to have further 





established and cholesterol synthetic regulation in the brain is still to be completely 
understood. 
Consistent with previous studies in the striatum of R6/1 [4] and R6/2 mice [7], our study did 
not detect any significant alteration to the level of cholesterol in striatum and cortex of R6/1 
mice compared to WT at any time-point. Previous studies also report conflicting results; a 
small but significant decrease in cholesterol levels was detected in whole brain of the YAC 
128 mouse model [17], and a significant increase of total striatal cholesterol was detected in a 
knock-in mouse model [4]. These contradictions are probably due to differences in 
cholesterol quantification methodologies used, that have been shown to significantly affect 
the result obtained [48]. Analysis of different brain regions (striatum or whole brain 
homogenates) are also likely to produce different results as there can be up to a 3-fold 
difference in cholesterol levels between brain regions [7,44]. 
As WT and R6/1 mice aged, cholesterol synthetic precursor levels (lathosterol, lanosterol, 
zymosterol and 24,25 dihydro lanosterol) decreased in the striatum, and to a lesser extent the 
cortex. A similar reduction with age has been observed in human brain tissue [47]. An 
increase in cholesterol levels during aging suggests that metabolic pathways may also have a 
significant involvement in maintaining brain cholesterol levels, which has major implications 
for brain ageing, an overarching risk factor across all neurodegenerative brain diseases. 
At 28 weeks of age a significant (25%) reduction of 24-OHC levels in the R6/1 striatum 
indicated that the relative decline of 24-OHC in R6/1 mice compared to WT is progressive 
over the course of the disease, becoming more pronounced at later stages. Previous studies 
have also identified a reduction of this metabolite in the brain and plasma of several other HD 
mouse models [7,8]. Here we have also identified that 24-OHC levels increase in cortex and 





with age in the mouse brain [20]. The importance of increased cholesterol metabolism in the 
ageing brain, and the potential effects of metabolic dysfunction in this HD model requires 
further investigation.  
A predominantly peripheral metabolite of cholesterol, 27-OHC was also significantly reduced 
in R6/1 striatum by the age of 12 weeks, while cortex tissue had no significant alterations. 27-
OHC has a net movement from circulation into the brain [29] and reduced levels seen in R6/1 
mice might be explained by a whole body metabolic dysfunction that is known to occur in 
HD [49,50]. However, cortex tissue did not exhibit the same reduction of 27-OHC levels 
observed in striatum, and therefore it is possible that enzymes that further metabolise 27-
OHC are upregulated, or enzymes capable of forming 27-OHC in brain are downregulated in 
striatum.  
Oxidation of cholesterol in the 5,6 position generates 7β-OHC and 7-KC that have been 
demonstrated to be stable and reliable markers of oxidative stress, previously used in plasma 
[36]. In contrast to our results that showed no change in COPs, a study in the striatum of R6/1 
mice did observe a time-dependant increase of lipid peroxidation using a less sensitive and 
specific lipid fluorescence based assay [51]. Since cholesterol is highly abundant in the brain, 
the presence of oxidative stress would be expected to increase the formation of COPs in the 
R6/1 mouse brain. Further research using oxidative damage biomarkers of multiple 
biomolecules in a variety of brain regions is required to understand the exact role that 
oxidative stress plays in the progression of HD pathophysiology. 
Previous literature has typically studied either male or female R6/1 mice, in separate studies. 
Here we have examined both sexes in parallel between 6 and 28 weeks of age to more 





Despite differences in human and mouse metabolism the CAG expansion in transgenic R6/1 
mice causes weight loss in line with that observed in human HD patients [52,53]. Consistent 
with previous reports we observed a milder weight loss phenotype in females compared to 
male R6/1 mice [54,55]. Female R6/1 weight gain was significantly slower than WT mice 
prior to significant weight loss from 19 week of age, suggesting a metabolic abnormality 
from early life. Body weight of male R6/1 mice was variable and a significant difference in 
weight gain prior to weight loss was not detected. The primary cause of weight loss is 
unlikely due to lack of feeding since it has been reported that R6/1 mice have a similar food 
intake to WT mice whilst still exhibiting a distinct weight loss profile [39]. Food intake of 
R6/1 mice was not measured in this study to reduce stress on animals being isolated and 
reunited. During the progression of disease in R6/1 mice, both male and female mice showed 
a progressive loss of motor skills that were quantified by Rotarod. Despite the same 
environmental and handling conditions, high variation between mice reduced the statistical 
power and gender differences in the progression of the motor deficit could not be 
conclusively demonstrated. Impaired motor performance at the end time-point was 
comparable between male and female R6/1 mice.  
In this study we have comprehensively profiled cholesterol synthetic and metabolic changes 
in R6/1 mice using GC-MS/MS and found similar reductions in the cholesterol synthetic 
precursors previously reported in the R6/2 model. The novel measurement of desmosterol 
and 7-dehydrocholesterol in R6/1 mice in this study has revealed potentially more complex 
dysregulation of the cholesterol synthetic pathway in HD. It has highlighted the specific 
accumulation of desmosterol in R6/1 brain tissue that is potentially due to reduced activity of 
DHCR24. Reduction of 24-OHC and 27-OHC in the striatum of R6/1 mice compared to WT 
littermates suggests that multiple pathways of cholesterol metabolism are perturbed in the 





mice during progression of HD provides a new insight into synthetic and metabolic changes 
occurring in this model of HD. Novel data on age-related changes occurring in the brain also 
offers further information on sterol-related mechanisms that may influence other 
neurodegenerative processes that typically manifest in the aged brain. 
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Fig. 1 Simplified pathway showing cholesterol synthesis, metabolism and free radical 
oxidation relevant to this study. The lower cholesterol synthetic (downstream of squalene) 
pathway is branched into the Kandutsch-Russell pathway (via lathosterol) and Bloch pathway 
(via desmosterol). Major metabolic pathways of cholesterol involve the enzymatic 
hydroxylation of cholesterol by; cholesterol 24-hydroxylase (CYP46A1) to form 24-
hydroxycholesterol (24-OHC), and cholesterol 27-hydroxylase (CYP27A1) to form 27-
hydroxycholesterol (27-OHC). Free radical mediated oxidation of cholesterol can also occur. 
Reactive oxygen species (ROS) form 7-Ketocholesterol and 7β-hydroxycholesterol. The 
position of delta(24)-sterol reductase (DHCR24), a cholesterol synthetic enzyme is also 
shown. Broken lines indicate intermediates that have not been shown in this simplified 
scheme 
Fig. 2 Progression of the physical phenotype in male and female R6/1 mice. (A) R6/1 mice 
had significantly reduced body weight compared to WT over the course of the study (p < 
0.0001). The R6/1 weight loss phenotype is more severe in male mice compared to females. 
Male R6/1 mice begin to lose weight after 16 weeks compared to 19 weeks in females. The 
rate of weight gain prior to weight loss was significantly slower in R6/1 females compared to 
WT (p = 0.00012) while no difference was observed in male mice. (B) R6/1 mice develop a 
phenotype where the hind paws are clasped to the body when suspended by the tail. Male 
R6/1 mice exhibited the phenotype prior to females; the occurrence of the phenotype 
increased in the population during ageing with 60% of the R6/1 mice showing a positive 
clasping phenotype by 28 weeks. A small proportion of WT mice appeared to exhibit a half 
clasp phenotype during the course of the study. (C) The motor performance of mice was 





and female mice to run on an accelerating rod when compared to WT (p = 0.0016 and 0.0004 
respectively). No difference between male and female mice with the same genotype was 
detected. Closed circles represent R6/1, open circles represent WT. n = 5 per group. Error 
bars represent ± SEM 
Fig. 3 Brain mass of R6/1 mice during disease progression. Brain mass was significantly 
reduced in both R6/1 male and female mice compared to WT at later stages. The difference 
between WT and R6/1 male mice was highly significant at 20, 24 and 28 weeks. A significant 
difference between R6/1 and WT female mice was detected at 12 and 20 weeks, becoming 
highly significant at 24 and 28 weeks. The brain mass was measured from mice sacrificed at 
lipid analysis time points; each point represents 5-7 mice. Closed circles represent R6/1, open 
circles represent WT. Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p < 
0.05 ***p < 0.0001 
Fig. 4 Cholesterol synthetic precursor levels in striatum tissue of R6/1 and WT littermates. 
Extracted sterols were quantified using heavy isotope mass dilution GC-MS/MS. (A) 
Lathosterol, (B) lanosterol and (C) zymosterol  levels were significantly reduced early in the 
R6/1 mice compared to WT. (D) 24,25 dihydro lanosterol showed a trend to be decreased in 
R6/1 mice however there was no significant difference between WT and R6/1 at any time-
point. Lanosterol, lathosterol, zymosterol and 24,25 dihydro lanosterol decreased over time in 
both R6/1 and WT mice (p < 0.01). (E) Desmosterol did not significantly decline in R6/1 
mice, and was significantly elevated at 20 and 28 weeks compared to control. (F) 7-
Dehydrocholesterol did not significantly decline in R6/1 mice and no significant differences 
were detected between R6/1 and WT at any time point. Each data point represents combined 
results from male and female mice, n = 10-13 per group. Closed circles represent R6/1, open 
circles represent WT. Error bars represent ± SEM. 2-way ANOVA Bonferroni post-test *p < 





Fig. 5 Cholesterol synthetic precursor levels in cortex tissue of R6/1 and WT littermates. 
Extracted sterols were quantified using heavy isotope mass dilution GC-MS/MS. (A) 
Lathosterol and (B) lanosterol levels were significantly reduced early in R6/1 mice compared 
to WT. (C) Zymosterol was significantly reduced in R6/1 at the end time point. (D) 24,25 
dihydro lanosterol  had a trend to be reduced however there was no significant difference 
between WT and R6/1 at any time-point. Zymosterol, lanosterol and 24,25 dihydro lanosterol 
decreased in R6/1 over time while WT levels remained unchanged (p < 0.01). Lathosterol 
levels decreased both in R6/1 and WT at a similar rate. (E) Desmosterol levels did not change 
over time in R6/1 or WT mice, however desmosterol was elevated in R6/1 mice at 28 weeks. 
(F) 7-Dehydrocholesterol did not significantly decline in R6/1 mice and no significant 
differences were detected between R6/1 and WT at any time point.  Each data point 
represents combined results from male and female mice, n = 10-13 per group. Closed circles 
represent R6/1, open circles represent WT. Error bars represent ± SEM. 2-way ANOVA 
Bonferroni post-test *p < 0.05 **p < 0.01 ***p < 0.0001. t-test Ψp < 0.05 
Fig. 6 The level of cholesterol and cholesterol metabolites in striatum and cortex tissue of 
R6/1 and WT littermates. Extracted sterols were quantified using heavy isotope mass dilution 
GC-MS/MS. 24(S)-Hydroxycholesterol was significantly reduced in striatum of R6/1 mice 
compared to WT at the end stage of the study. A significant reduction in 27-
hydroxycholesterol levels was detected at 12, 20, 24 and 28 weeks in the R6/1 striatum. An 
effect of genotype on cortical levels of 24-hydroxycholesterol and 27-hydroxycholesterol was 
not detected at any time point. Cholesterol levels were unaltered between R6/1 and WT mice 
in both striatum and cortex at all time-points examined. A significant increase in 24-
hydroxycholesterol and cholesterol levels over time was detected in both regions (p < 0.01 





mice, n = 10-13 per group. Closed circles represent R6/1, open circles represent WT. Error 



















































































































6 week  12 week 20 week  24 week 28 week







Lathosterol 54.8 ± 5.6  41.7 ± 6.7 43.2 ± 6.2 20.0 ± 4.8 41.6 ± 5.7 17.8 ± 6.1 43.8 ± 10.7 12.6 ± 3.5 31.4 ± 6.0 8.7 ± 2.7 
Lanosterol 13.6 ± 3.8  13.1 ± 3.6 10.8 ± 1.7 8.3 ± 2.5 13.6 ± 2.7 8.7 ± 3.4 12.2 ± 4.0 4.5 ± 1.3 8.9 ± 2.5* 4.7 ± 1.7 
Zymosterol 5.0 ± 1.3  4.0 ± 0.9 3.2 ± 0.4 2.2 ± 0.4 2.9 ± 0.63 2.2 ± 0.83 3.5 ± 0.88 1.8 ± 0.36 2.7 ± 0.4 1.5 ± 0.6 
24,25 diH lan. 0.34 ± 0.22  0.39 ± 0.19 0.33 ± 0.09 0.24 ± 0.18 0.26 ± 0.05 0.19 ± 0.06 0.31 ± 0.07 0.20 ± 0.07 0.19 ± 0.09 0.13 ± 0.08 
Desmosterol 57.0 ± 9.1  57.7 ± 3.8* 31.1 ± 9.6* 39.7 ± 17.2 35.8 ± 5.1 41.7 ± 12.6 39.8 ± 8.1 42.0 ± 4.6 33.0 ± 5.9 40.1 ± 7.3 
7‐DHC 63.0 ± 15.9  59.0 ± 4.9* 43.5 ± 22.4 48.4 ± 21.8 54.3 ± 16.8 46.7 ± 14.6 37.9 ± 7.0 42.5 ± 12.6 57.3 ± 15.3 68.7 ± 15.3 
24‐OHC 48.5 ± 8.7*  42.3 ± 4.8* 46.8 ± 4.1 39.7 ± 4.1 57.6 ± 11.2 48.6 ± 15.1 53.3 ± 8.5 45.5 ± 5.2 53.7 ± 3.4* 40.5 ± 8.3 
27‐OHC 0.039 ± 0.02  0.034 ± 0.01 0.078 ± 0.02 0.051 ± 0.01 0.083 ± 0.03 0.052 ± 0.02 0.075 ± 0.012 0.051 ± 0.014 0.043 ± 0.02 0.024 ± 0.01 
7‐KC 0.67 ± 0.26  0.66 ± 0.29* 0.65 ± 0.18 0.65 ± 0.15 0.30 ± 0.003 0.28 ± 0.009 0.58 ± 0.19 0.52 ± 0.11 0.65 ± 0.29 0.41 ± 0.17 
7β‐OHC 0.36 ± 0.12  0.36 ± 0.17 0.45 ± 0.19 0.54 ± 0.27 0.26 ± 0.005 0.26 ± 0.010 0.21 ± 0.06 0.22 ± 0.06 0.28 ± 0.13 0.23 ± 0.11 






Lathosterol 33.5 ± 8.7  27.7 ± 11.2 34.7 ± 14.8 14.8 ± 4.1 34.5 ± 10.8 19.5 ± 3.1 32.1 ± 11.9 14.8 ± 3.3 28.8 ± 5.5 14.6 ± 3.1 
Lanosterol 7.9 ± 1.4  8.3 ± 2.9 7.9 ± 2.7 5.7 ± 1.4 12.3 ± 4.7 7.4 ± 1.7 6.7 ± 2.3 4.2 ± 1.2 8.4 ± 1.3 4.6 ± 1.2 
Zymosterol 2.4 ± 0.66  2.9 ± 1.1 2.9 ± 0.6 2.5 ± 0.6 2.7 ± 0.6 2.0 ± 0.3 3.0 ± 1.2 2.7 ± 0.85 2.9 ± 0.30 2.0 ± 0.42 
24,25 diH lan. 0.33 ± 0.06  0.40 ± 0.17 0.32 ± 0.11 0.22 ± 0.07 0.37 ± 0.18 0.32 ± 0.17 0.22 ± 0.07 0.14 ± 0.04 0.32 ± 0.03 0.25 ± 0.09 
Desmosterol 32.8 ± 14.9  36.8 ± 9.2 34.6 ± 16.3 42.4 ± 16.4 41.9 ± 12.9* 47.3 ± 7.3 27.0 ± 9.5 33.1 ± 9.4 32.0 ± 8.1 38.0 ± 2.1 
7‐DHC 39.5 ± 17.2  41.2 ± 9.9 39.9 ± 6.0 40.5 ± 12.0 44.1 ± 6.4 44.5 ± 13.2 31.0 ± 7.0 30.6 ± 9.9 45.6 ± 7.4 49.7 ± 6.2 
24‐OHC 28.4 ± 9.5  27.3 ± 7.5 29.7 ± 7.8 33.5 ± 7.5 40.3 ± 7.7 37.4 ± 9.0 23.6 ± 5.7* 26.2 ± 6.7 46.3 ± 6.7 42.4 ± 6.7 
27‐OHC 0.038 ± 0.02  0.030 ± 0.008 0.037 ± 0.01 0.038 ± 0.01 0.099 ± 0.06* 0.071 ± 0.03* 0.034 ± 0.007 0.032 ± 0.011 0.051 ± 0.008 0.044 ± 0.01 
7‐KC 0.27 ± 0.12*  0.32 ± 0.13 0.51 ± 0.04 0.50 ± 0.09 0.37 ± 0.11 0.58 ± 0.16 0.31 ± 0.08 0.22 ± 0.04* 0.86 ± 0.50 1.0 ± 1.05 
7β‐OHC 0.14 ± 0.07  0.18 ± 0.10 0.40 ± 0.11 0.35 ± 0.14 0.12 ± 0.03 0.16 ± 0.12 0.12 ± 0.02 0.15 ± 0.07 0.43 ± 0.30 0.20 ± 0.09 















6 week  12 week 20 week  24 week 28 week







Lathosterol 58.5 ± 13.7  36.4 ± 8.3 46.6 ± 14.8 19.7 ± 6.6 48.3 ± 4.1 18.7 ± 6.4 33.5 ± 8.9 17.7 ± 6.8 36.4 ± 7.8 5.7 ± 1.9 
Lanosterol 17.1 ± 6.7  10.2 ± 3.3 14.8 ± 5.9 7.9 ± 2.8 15.2 ± 4.3 8.3 ± 3.4 9.8 ± 4.3 6.4 ± 1.9 13.3 ± 3.0* 2.7 ± 1.4 
Zymosterol 5.1 ± 1.2  3.6 ± 0.93 3.6 ± 1.3 2.1 ± 0.8 3.1 ± 0.74 1.9 ± 0.43 3.0 ± 1.2 2.3 ± 0.98 2.7 ± 0.3 1.1 ± 0.8 
24,25 diH lan. 0.44 ± 0.22  0.20 ± 0.14 0.51 ± 0.26 0.33 ± 0.20 0.30 ± 0.03 0.21 ± 0.05 0.33 ± 0.012 0.23 ± 0.05 0.21 ± 0.12 0.04 ± 0.03 
Desmosterol 53.7 ± 9.1  42.9 ± 8.2* 47.8 ± 9.1* 40.4 ± 6.8 33.0 ± 5.0 41.3 ± 6.5 37.0 ± 6.7 45.1 ± 5.4 33.4 ± 5.1 39.4 ± 4.0 
7‐DHC 70.9 ± 13.2  46.9 ± 5.3* 56.8 ± 21.0 52.3 ± 10.6 45.3 ± 16.8 44.0 ± 13.2 42.9 ± 14.0 47.7 ± 16.6 56.5 ± 10.8 55.4 ± 16.1 
24‐OHC 38.1 ± 7.5*  34.8 ± 3.6* 45.1 ± 4.2 43.1 ± 3.1 56.5 ± 4.7 49.5 ± 7.9 46.5 ± 5.6 43.6 ± 7.4 61.9 ± 6.8* 49.3 ± 4.6 
27‐OHC 0.034 ± 0.02  0.030 ± 0.01 0.067 ± 0.01 0.046 ± 0.02 0.071 ±  0.049 ± 0.12 0.078 ± 0.02 0.056 ± 0.008 0.058 ± 0.02 0.028 ± 0.009 
7‐KC 0.84 ± 0.57  0.33 ± 0.06* 0.60 ± 0.21 0.70 ± 0.16 0.33 ± 0.008 0.32 ± 0.008 0.49 ± 0.18 0.57 ± 0.19 0.38 ± 0.05 0.57 ± 0.19 
7β‐OHC 0.35 ± 0.28  0.20 ± 0.05 0.44 ± 0.12 0.57 ± 0.18 0.23 ± 0.004 0.23 ± 0.005 0.20 ± 0.07 0.24 ± 0.06 0.20 ± 0.07 0.25 ± 0.13 






Lathosterol 40.2 ± 10.3  26.3 ± 10.4 43.9 ± 9.9 21.2 ± 6.1 41.6 ± 8.8 15.5 ± 6.3 31.8 ± 7.9 15.6 ± 1.7 30.6 ± 6.1 15.3 ± 4.0 
Lanosterol 9.4 ± 3.5  7.4 ± 1.1 10.4 ± 3.3 7.0 ± 1.5 10.9 ± 2.6 5.5 ± 1.6 9.5 ± 2.2 4.6 ± 0.99 9.6 ± 0.94 5.3 ± 1.7 
Zymosterol 2.6 ± 0.44  2.7 ± 0.69 3.2 ± 0.6 2.8 ± 0.4 2.4 ± 0.5 1.9 ± 0.6 3.8 ± 0.94 2.7 ± 0.65 2.8 ± 0.50 2.0 ± 0.48 
24,25 diH lan. 0.45 ± 0.16  0.35 ± 0.08 0.35 ± 0.15 0.24 ± 0.11 0.32 ± 0.08 0.17 ± 0.11 0.27 ± 0.07 0.14 ± 0.05 0.32 ± 0.05 0.23 ± 0.04 
Desmosterol 29.6 ± 5.1  36.8 ± 10.0 33.6 ± 16.7 47.6 ± 18.6 26.1 ± 7.3* 44.0 ± 2.9 34.8 ± 12.5 39.5 ± 12.2 32.8 ± 7.9 38.5 ± 4.3 
7‐DHC 40.6 ± 4.9  39.1 ± 9.4 38.1 ± 6.1 41.8 ± 15.1 42.5 ± 7.3 46.0 ± 16.6 24.1 ± 7.5 31.3 ± 11.3 49.2 ± 5.5 50.4 ± 9.6 
24‐OHC 26.6 ± 4.8  30.9 ± 7.6 30.4 ± 4.8 32.6 ± 2.5 38.7 ± 17.4 37.2 ± 3.6 38.5 ± 9.5* 32.9 ± 5.8 45.8 ± 10.9 37.8 ± 3.7 
27‐OHC 0.034 ± 0.008  0.033 ± 0.008 0.044 ± 0.02 0.047 ± 0.01 0.021 ± 0.006* 0.017 ± 0.005* 0.060 ± 0.03 0.039 ± 0.01 0.055 ± 0.007 0.033 ± 0.007 
7‐KC 0.49 ± 0.18*  0.33 ± 0.11 0.49 ± 0.17 0.46 ± 0.18 0.46 ± 0.22 0.51 ± 0.25 0.33 ± 0.10 0.35 ± 0.11* 0.91 ± 0.62 0.78 ± 0.68 
7β‐OHC 0.24 ± 0.12  0.22 ± 0.14 0.37 ± 0.17 0.37 ± 0.12 0.15 ± 0.06 0.16 ± 0.04 0.11 ± 0.02 0.18 ± 0.06 0.35 ± 0.35 0.23 ± 0.11 














6 week  12 week 20 week  24 week 28 week







Lathosterol 56.5 ± 9.6  38.8 ± 7.8 45.0 ± 11.3 19.8 ± 5.6 44.6 ± 6.0 18.3 ± 5.9 38.6 ± 10.7 14.9 ± 5.6 33.9 ± 7.0 7.2 ± 2.7 
Lanosterol 15.2 ± 5.4  11.5 ± 3.6 12.9 ± 4.8 8.1 ± 2.5 14.3 ± 3.4 8.5 ± 3.2 11.0 ± 4.1 5.4 ± 1.9 11.1 ± 3.5 3.7 ± 1.8 
Zymosterol 5.0 ± 1.2  3.8 ± 0.88 3.5 ± 0.9 2.2 ± 0.6 3.0 ± 0.65 2.0 ± 0.65 3.7 ± 1.0 2.0 ± 0.71 2.7 ± 0.33 1.3 ± 0.72 
24,25 diH lan. 0.38 ± 0.21  0.29 ± 0.19 0.44 ± 0.22 0.29 ± 0.19 0.28 ± 0.05 0.20 ± 0.05 0.32 ± 0.09 0.21 ± 0.06 0.20 ± 0.10 0.090 ± 
Desmosterol 55.5 ± 8.9  49.6 ± 9.9 40.2 ± 12.4 40.1 ± 11.9 34.5 ± 5.0 41.5 ± 9.5 38.4 ± 7.2 43.4 ± 5.0 33.2 ± 5.2 39.8 ± 5.6 
7‐DHC 66.6 ± 14.7  52.2 ± 7.8 50.8 ± 21.6 50.5 ± 15.8 50.2 ± 16.6 45.2 ± 13.2 40.4 ± 10.8 44.9 ± 14.0 56.9 ± 12.8 62.2 ± 16.4 
24‐OHC 43.7 ± 9.5  38.2 ± 5.6 45.5 ± 4.1 41.0 ± 3.6 57.1 ± 8.5 49.1 ± 11.4 49.9 ± 7.7 44.6 ± 6.0 57.8 ± 6.7 44.9 ± 7.8 
27‐OHC 0.037 ±  0.033 ±  0.071 ±  0.047 ±  0.77 ± 0.02 0.51 ± 0.15 0.076 ± 0.02 0.053 ± 0.01 0.051 ±  0.026 ± 
7‐KC 0.74 ± 0.40  0.48 ± 0.26 0.59 ± 0.17 0.67 ± 0.15 0.032 ± 0.006 0.030 ± 0.008 0.53 ± 0.18 0.54 ± 0.15 0.52 ± 0.24 0.49 ± 0.19 
7β‐OHC 0.36 ± 0.19  0.27 ± 0.14 0.42 ± 0.15 0.54 ± 0.22 0.24 ±  0.025 ± 0.007 0.21 ± 0.06 0.23 ± 0.06 0.24 ± 0.11 0.24 ± 0.11 






Lathosterol 36.6 ± 9.7  27.0 ± 10.2 39.7 ± 9.3 18.3 ± 6.1 35.8 ± 9.5 17.5 ± 5.1 31.9 ± 9.5 15.2 ± 2.6 29.7 ± 5.6 15.0 ± 3.5 
Lanosterol 8.6 ± 2.6  7.8 ± 2.0 9.2 ± 3.2 6.4 ± 1.5 7.7 ± 2.4 4.5 ± 1.3 8.1 ± 2.6 4.4 ± 1.1 9.0 ± 1.2 5.0 ± 1.4 
Zymosterol 2.5 ± 0.55  2.8 ± 0.84 3.0 ± 0.6 2.7 ± 0.5 2.5 ± 0.4 1.9 ± 0.4 3.4 ± 1.1 2.7 ± 0.73 2.9 ± 0.39 2.0 ± 0.42 
24,25 diH lan. 0.39 ± 0.12  0.37 ± 0.12 0.34 ± 0.13 0.23 ± 0.09 0.32 ± 0.12 0.25 ± 0.15 0.24 ± 0.06 0.14 ± 0.04 0.32 ± 0.04 0.24 ± 0.07 
Desmosterol 31.3 ± 11.2  36.6 ± 9.2 34.1 ± 15.7 45.3 ± 17.0 35.3 ± 14.0 45.7 ± 5.5 30.9 ± 11.2 36.0 ± 10.7 32.4 ± 7.5 38.3 ± 3.2 
7‐DHC 40.0 ± 12.6  40.1 ± 9.2 42.8 ± 6.4 45.3 ± 14.4 43.3 ± 6.5 45.3 ± 14.4 27.6 ± 7.7 30.9 ± 10.0 47.4 ± 6.4 50.0 ± 7.6 
24‐OHC 27.5 ± 7.5  29.3 ± 7.5 30.1 ± 6.0 33.0 ± 5.1 39.6 ± 13.0 37.3 ± 6.5 31.0 ± 10.8 29.2 ± 6.9 46.1 ± 8.5 40.1 ± 5.6 
27‐OHC 0.036 ±  0.032 ± 0.007 0.041 ±  0.043 ±  0.047 ±  0.044 ±  0.047 ± 0.02 0.035 ± 0.01 0.053 ± 0.007 0.039 ± 
7‐KC 0.37 ± 0.18  0.33 ± 0.11 0.50 ± 0.12 0.48 ± 0.14 0.41 ± 0.17 0.54 ± 0.20 0.32 ± 0.08 0.29 ± 0.11 0.88 ± 0.53 0.90 ± 84 
7β‐OHC 0.19 ± 0.11  0.20 ± 0.12 0.38 ± 0.14 0.36 ± 0.13 0.13 ±  0.16 ±  0.11 ± 0.02 0.16 ± 0.07 0.40 ± 0.30 0.22 ± 0.09 
Cholesterola 10.1 ± 2.4  9.2 ± 2.5 15.4 ± 2.7 15.0 ± 2.1 11.0 ± 2.5 11.9 ± 1.7 11.4 ± 2.5 10.7 ± 1.7 15.5 ± 1.7 16.4 ± 3.1 
